INTRODUCTION: To estimate the costs of palliative care for colorectal cancer (CRC) from the perspective of German statutory health insurance and to measure the patients' quality of life (QoL) for a 2-year time period. METHODS: A prospective observational multicentre study was carried out to estimate the direct costs of care over a 2-year period. Case report forms, medical records, and claims data were all applied to document medical and resource usage data in real-world settings. QoL was measured by using the Short Form-12 Health Survey. RESULTS: In total 101 patients (mean age 67.09 ± 11.13 years, 68 % male) from 12 different settings were included. The mean costs per patient during the 1st and 2nd years were calculated to be 42,361€ and 32,023€, respectively. Highest mean costs were calculated for the second quarter, which reached an amount of 12,900€ (95 % CI: 11,127€-14,673€). Mean physical summary scores and mean mental summary scores were 41.8 and 49.7, respectively. DISCUSSION: This is the first study assessing the costs of palliative care and the quality of life of patients with CRC in real-world health-care delivery in Germany. It could be shown that CRC treatment represents an enormous economic burden to the German health-care system. Increased efforts in promoting effective and efficient treatment options, or performance-based medication reimbursement schemes, might be helpful in reducing the costs.
INTRODUCTION: To estimate the costs of palliative care for colorectal cancer (CRC) from the perspective of German statutory health insurance and to measure the patients' quality of life (QoL) for a 2-year time period. METHODS: A prospective observational multicentre study was carried out to estimate the direct costs of care over a 2-year period. Case report forms, medical records, and claims data were all applied to document medical and resource usage data in real-world settings. QoL was measured by using the Short Form-12 Health Survey. RESULTS: In total 101 patients (mean age 67.09 ± 11.13 years, 68 % male) from 12 different settings were included. The mean costs per patient during the 1st and 2nd years were calculated to be 42,361€ and 32,023€, respectively. Highest mean costs were calculated for the second quarter, which reached an amount of 12,900€ (95 % CI: 11,127€-14,673€). Mean physical summary scores and mean mental summary scores were 41.8 and 49.7, respectively. DISCUSSION: This is the first study assessing the costs of palliative care and the quality of life of patients with CRC in real-world health-care delivery in Germany. It could be shown that CRC treatment represents an enormous economic burden to the German health-care system. Increased efforts in promoting effective and efficient treatment options, or performance-based medication reimbursement schemes, might be helpful in reducing the costs.
Authors: John R C Wheeler; Bert White; Simone Rauscher; Tammie A Nahra; Kristin L Reiter; Kathleen M Curtin; Cheryl L Damberg Journal: J Health Care Finance Date: 2007
Authors: W Schmiegel; A Reinacher-Schick; D Arnold; U Graeven; V Heinemann; R Porschen; J Riemann; C Rödel; R Sauer; M Wieser; W Schmitt; H-J Schmoll; T Seufferlein; I Kopp; C Pox Journal: Z Gastroenterol Date: 2008-08 Impact factor: 2.000
Authors: S Lopatriello; D Amoroso; S Donati; O Alabiso; L Forti; A Fornasiero; A Smergo; A Lalli; C Iacono; A Lucenti; L D'Alonzo; C Negrini Journal: Eur J Cancer Date: 2008-09-18 Impact factor: 9.162
Authors: Josh J Carlson; Sean D Sullivan; Louis P Garrison; Peter J Neumann; David L Veenstra Journal: Health Policy Date: 2010-03-11 Impact factor: 2.980
Authors: A Wein; C Riedel; W Brückl; S Merkel; R Ott; B Hanke; U Baum; F Fuchs; K Günther; T Reck; T Papadopoulos; E G Hahn; W Hohenberger Journal: Oncology Date: 2003 Impact factor: 2.935
Authors: Hans-Helmut König; Dirk Heider; Thomas Lehnert; Steffi G Riedel-Heller; Matthias C Angermeyer; Herbert Matschinger; Gemma Vilagut; Ronny Bruffaerts; Josep M Haro; Giovanni de Girolamo; Ron de Graaf; Viviane Kovess; Jordi Alonso Journal: Health Qual Life Outcomes Date: 2010-11-29 Impact factor: 3.186
Authors: D J Watkins; I Chau; D Cunningham; S S Mudan; N Karanjia; G Brown; S Ashley; A R Norman; A Gillbanks Journal: Br J Cancer Date: 2010-01-19 Impact factor: 7.640
Authors: Bruno A Cisterna; Nazila Kamaly; Won Il Choi; Ali Tavakkoli; Omid C Farokhzad; Cristian Vilos Journal: Nanomedicine (Lond) Date: 2016-08-16 Impact factor: 5.307
Authors: Sonja Koch; Axel Wein; Jürgen Siebler; Frank Boxberger; Markus F Neurath; Hanns-Detlev Harich; Werner Hohenberger; Frank Dörje Journal: Support Care Cancer Date: 2013-04-09 Impact factor: 3.603
Authors: Kathrin Borchert; Christian Jacob; Natalie Wetzel; Martina Jänicke; Egbert Eggers; Annette Sauer; Norbert Marschner; Julia Altevers; Thomas Mittendorf; Wolfgang Greiner Journal: Health Econ Rev Date: 2020-12-12